- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
NICE says ‘no’ to talimogene laherparepvec in melanoma
16 March 2016 • Author: Victoria White
The National Institute for Health and Care Excellence (NICE) has issued draft guidance not recommending Amgen’s Imlygic (talimogene laherparepvec) as an option for people with melanoma that has spread and can’t be surgically removed.
Talimogene laherparepvec is a modified form of the herpes simplex virus type-1 (HSV-1) that normally causes cold sores. In its altered state it is designed to kill cancer cells both by directly attacking them and also by helping the immune system recognise and destroy them. Talimogene laherparepvec is injected directly into the skin tumour.
Commenting on the announcement, Professor Carole Longson MBE, Director of the Centre for Health Technology Evaluation at NICE, said: “Up until very recently the treatments available for advanced melanoma were very limited and in some cases restricted to palliative care. Talimogene laherparepvec represents an innovative approach to the treatment of the disease.
“The committee heard from the patient and clinical experts that because the drug has fewer side effects than other drugs for advanced melanoma, it would be particularly valuable to some people with this condition.
“However, the committee concluded that there was not enough evidence to be able to say whether talimogene laherparepvec is as clinically effective as other drugs used to treat advanced melanoma. Given the uncertainty about its effect on overall survival compared with these drugs it was not possible to recommend talimogene laherparepvec as a cost-effective use of NHS resources.”
NICE recently made recommendations for other therapies in melanoma
Last month NICE recommended nivolumab (Opdivo, Bristol Myers Squibb) for advanced melanoma. NICE has also recommended ipilimumab (Yervoy Bristol-Myers Squibb) as a possible treatment for adults with advanced melanoma that has either not been treated before or that has previously been treated. In addition, NICE recommends pembrolizumab (Keytruda, Merck Sharp & Dohme) for advanced melanoma used before and after prior treatment with ipilimumab.
Consultees, including the company, healthcare professionals and members of the public have until 13 April to comment on the preliminary guidance. Comments received during this consultation will be fully considered by the Committee at its meeting on 19 April and following this meeting the next draft guidance will be issued.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Sentronic GmbH Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited WITec GmbH Xylem Analytics YMC Europe GmbH Yusen Logistics